Clinical Trial Update: An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia [Phase 2]

View source ↗

Summary

This is a Phase 2 open-label study evaluating ACP-196 (acalabrutinib) in patients with Waldenström macroglobulinemia. The study results were posted in April 202…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• ACP-196 (acalabrutinib)

Snippet

Sponsor: Acerta Pharma BV | Conditions: Waldenström Macroglobulinemia (WM) | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2020-04-24